Company Filing History:
Years Active: 2014-2017
Title: Michael Schickler: Innovator in Monoclonal Antibody Therapy
Introduction
Michael Schickler is a prominent inventor based in Mazkeret Batya, Israel. He has made significant contributions to the field of monoclonal antibody therapy, particularly in the treatment of cancer patients. With a total of 3 patents to his name, Schickler's work is paving the way for innovative therapeutic approaches.
Latest Patents
One of Schickler's latest patents is titled "Pidilizumab monoclonal antibody therapy following stem cell transplantation." This invention focuses on methods for treating specific populations of cancer patients, particularly those undergoing stem cell transplantation who have been classified as positive by pre-transplant metabolic imaging. The therapy involves administering a therapeutically effective amount of pidilizumab monoclonal antibody to the subject.
Another significant patent is "Variants of humanized immunomodulatory monoclonal antibodies." This invention relates to humanized monoclonal antibodies and pharmaceutical compositions that include them. The use of these antibodies is aimed at treating various indications, especially cancer and immunodeficiency disorders. The invention provides modified antibodies or fragments with specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.
Career Highlights
Michael Schickler is currently associated with Curetech Ltd., where he continues to advance his research and development in the field of immunotherapy. His work is characterized by a commitment to improving treatment options for patients suffering from serious health conditions.
Collaborations
Schickler collaborates with Rinat Rotem-Yehudar, contributing to the innovative research environment at Curetech Ltd. Their combined expertise enhances the potential for groundbreaking discoveries in monoclonal antibody therapies.
Conclusion
Michael Schickler's contributions to the field of monoclonal antibody therapy are noteworthy and impactful. His innovative patents and ongoing work at Curetech Ltd. reflect a dedication to advancing medical science and improving patient outcomes.